Добавил:
Sekretar
kiopkiopkiop18@yandex.ru
t.me/Prokururor I Вовсе не секретарь, но почту проверяю
Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз:
Предмет:
Файл:Ординатура / Хирургия / @xirurgi_2025 / @xirurgi_2025 - 1146 - файл
.pdf
152
https://t.me/med1917
S. A. Aljiburi et al.
B. Anal cancer’s etiology is more similar to genital malignancies than it is to
gastrointestinal tract cancers.
C. Solid organ transplant is a risk factor.
D. Antiretroviral therapy (ART) eliminates the risk of developing anal cancer
in HIV patients.
E. High-grade squamous intraepithelial lesions (HSIL) are associated with all
CD4+ strata in patients with HIV.
Answer: D
Explanation: Initial studies did not conclusively establish that ART eliminates the risk of developing anal cancer in HIV patients. More recent
research suggests a modest protective effect of ART, but the impact may be
limited in a population with a high prevalence of squamous intraepithelial
lesions (SIL).
3. In the context of human papillomavirus (HPV) and anal cancer, a 45-year-old
male patient presents with anal cancer. His medical history includes multiple
sexual partners and a recent diagnosis of HPV infection. The incorrect
statement is:
A. HPV is the most common sexually transmitted disease in the United States.
B. HPV 16 presence is also associated with a poor prognosis.
C. Infection with high-risk strains of HPV is associated with more than 90% of
cases of anal cancer.
D. HPV 16-associated anal SCC can be identied histologically by immuno-
histochemical expression of p16.
E. Quadrivalent HPV vaccine prevents HPV types 6, 11, 16, and 18.
Answer: B
Explanation: Contrary to the misconception, HPV 16 presence is associ-
ated with a good prognosis in anal cancer cases.
4. Regarding the anatomy of the anal canal, and during an examination of a patient
with rectal complaints, you are assessing the anatomy of the anal canal. The
incorrect statement is:
A. The length of the anatomical anal canal is 5cm long.
B. It begins where the rectum enters the puborectalis sling.
C. It ends roughly at the palpable intersphincteric groove.
D. The dentate line is a macroscopically visible landmark that overlies the
transition from glandular to squamous mucosa.
E. The anal sphincter complex is palpable as the anorectal ring on digital rectal
examination.
Answer: A
Explanation: The anatomical anal canal is, on average, 2.5–3.5cm long,
while the surgical anal canal measures 5cm. Understanding this distinction
is vital for accurate assessment in clinical practice.
5. In anal intraepithelial neoplasia (AIN) of the anal canal, you are managing a
35-year-old patient with AIN and discussing treatment options. The incorrect
statement is:
11 Anal Cancers
https://t.me/med1917
153
A. AIN I recurrence usually has an indolent course.
B. Local excision should only be considered if lesions cover less than one-
third of the anal circumference.
C. In AIN II/III, wide-local excision leads to recurrence in 1/3 of cases at 1year.
D. Anoscopy should be performed every 4–6months in AIN II/III.
E. Watchful waiting is the standard in recurrence of AIN I.
Answer: C
Explanation: Contrary to the statement, in AIN II/III, wide-local excision can lead to recurrence in approximately 2/3 of cases at 1 year.
Understanding the management and outcomes of AIN is crucial for
patient care.
6. Regarding the anatomy of the anal canal, you are conducting a proctologic
examination on a patient presenting with anal discomfort. The incorrect
statement is:
A. The internal anal sphincter is involuntary.
B. Hemorrhoids can be a sign of portal hypertension.
C. The perianus extends 5cm laterally from the anal verge.
D. The perianus is characterized by the presence of hair follicles and glands.
E. The anal pecten is superior to the dentate line.
Answer: E
Explanation: Above the dentate line, the epithelium is mucous membrane-like, while inferior to the dentate line, a transition zone known as the
anal pecten is lined by nonkeratinized stratied squamous epithelium.
Understanding the location and characteristics of the anal pecten is essential
for clinical assessment.
7. In the context of anatomy of the anal canal, during an examination of a patient
with anal discomfort, you are assessing the anatomy of the anal canal. The
incorrect statement is:
A. The anorectal junction is located 2–3cm in front and a little below the tip of
the coccyx.
B. In males, it is surrounded by the membranous urethra anteriorly.
C. Anal columns contain the inferior rectal veins.
D. The oor of the anal sinuses contains the opening to the anal glands.
E. Under anesthesia, the pectinate line can be observed.
Answer: C
Explanation: Contrary to common understanding, anal columns contain
the superior rectal veins, which is a key distinction in understanding the
vascular anatomy of the anal canal.
8. In levator ani anatomy, during a surgical procedure for pelvic organ prolapse,
you are considering the anatomy of the levator ani muscle. The incorrect
statement is:
A. Puborectalis and the pubococcygeus are located medially and superiorly.
B. Levator ani muscle is thick anteriorly.
154
https://t.me/med1917
S. A. Aljiburi et al.
C. It is mostly thin and aponeurotic posteriorly.
D. Iliococcygeus is primarily innervated by the sacral S1 and S2 nerves.
E. Pubococcygeus and the puborectalis muscles are primarily innervated by
the pudendal nerve.
Answer: D
Explanation: The statement about the innervation of the iliococcygeus
muscle is incorrect. Iliococcygeus is primarily innervated by the sacral S3
and S4 nerves, which is an important detail in understanding pelvic oor
anatomy and function.
9. In the context of SIL of the anal canal, you are reviewing the management of a
30-year-old female patient with a history of HPV infection and anal SIL.The
incorrect statement is:
A. Low-grade squamous intraepithelial lesions (LSIL) represent a marker for
risk of HSIL rather than a direct precursor.
B. LSIL may spontaneously regress.
C. HSIL containing HPV 16 are the least likely to regress.
D. Biopsy of small HSIL lesions contributes to its regression.
E. HPV vaccination has a role in preventing the progression of HSIL to inva-
sive anal cancer.
Answer: E
Explanation: Contrary to popular belief, HPV vaccination does not
induce regression of pre-existing HSIL, and it does not play a role in preventing the progression of HSIL to invasive anal cancer. It primarily provides protection against new HPV infections.
10. In the staging of anal cancers, you are assessing the staging and management of
a 55-year-old male patient newly diagnosed with anal cancer. The incorrect
statement is:
A. The probability of nodal spread is directly related to the tumor size.
B. Perianal skin cancers are staged and treated like squamous cell skin cancers.
C. There are no tumor markers that are consistently elevated in anal SCC.
D. Surgical staging is no longer performed routinely.
E. At initial presentation, most patients have a T1 or T2 lesion, and fewer than
20% are node-positive.
Answer: B
Explanation: The staging for perianal skin cancers has changed; they are
now staged and treated like anal canal cancers rather than squamous cell
skin cancers. Understanding this shift in staging is important for accurate
diagnosis and management.
11. In the context of histopathology of the anal canal, a 55-year-old male patient
presents with a suspicious anal lesion, and a biopsy is performed. The incorrect
statement is:
A. The anal verge is where the squamous mucosa merges with the perianal skin.
11 Anal Cancers
https://t.me/med1917
155
B. The term “anal cancer,” by common denition, refers to SCCs arising
within the mucosa of the anus.
C. Basaloid tumors are the older terms for nonkeratinizing types of SCC.
D. Tumors originating above the dentate line spread to the supercial inguinal
and external iliac (deep inguinal) nodes.
E. Adenocarcinomas arising from glandular elements within the anal canal
are rare.
Answer: D
Explanation: Contrary to common belief, tumors originating above the
dentate line, similar to rectal cancers, primarily drain to the mesorectal and
internal iliac nodes. It is essential to distinguish this nodal spread pattern.
12. In the treatment of anal cancer, you are discussing treatment options with a
50-year-old patient diagnosed with anal canal SCC.The incorrect statement is:
A. Surgery is the initial treatment rather than upfront concurrent CRT for anal
canal SCCs.
B. Concurrent use of uorouracil plus mitomycin during RT is the preferred
regime for most patients.
C. Cisplatin has less hematologic toxicity compared to mitomycin.
D. There is no role for induction chemotherapy or a continuation of chemo-
therapy beyond concurrent CRT.
E. Cisplatin is more active in the treatment of SCCs than is mitomycin.
Answer: A
Explanation: Contrary to the statement, initial concurrent CRT rather
than upfront surgery is recommended for most patients with anal canal
SCC. CRT has become the preferred method of treatment for anal canal
SCCs because it can cure many patients while preserving the anal sphincter
in a signicant percentage of cases. Understanding the preferred treatment
approach is essential for managing these patients effectively.
13. In the therapy of anal cancer, you are discussing treatment options with a
55-year-old patient diagnosed with early-stage anal cancer. The incorrect
statement is:
A. Patients with active HIV/AIDS-related complications may require dose
adjustment.
B. RT dose is 45Gy for early-stage disease.
C. Isolated para-aortic LN involvement is common.
D. The total dose of RT in node-positive disease is 55–59Gy.
E. There is no benet in intensifying treatment for locally advanced disease.
Answer: C
Explanation: Isolated para-aortic LN involvement is rare and considered
M1 (stage IV) disease in the context of anal cancer. Understanding the staging and treatment implications for such cases is crucial for accurate
management.
14. In the treatment guidelines of anal cancer, you are following up with a patient
who underwent treatment for anal cancer. The incorrect statement is:
156
https://t.me/med1917
S. A. Aljiburi et al.
A. Local excision is standard of care for patients with T1 tumors less than 1cm
in size.
B. Vigilant follow-up soon after resection is mandatory.
C. After 3years, extended imaging surveillance is not indicated.
D. MRI is indicated at 8–12 weeks posttreatment to assess the patient’s
response.
E. SCCs regress slowly.
Answer: D
Explanation: Contrary to the statement, posttreatment assessment by
MRI at 8–12 weeks is not recommended for evaluating the patient’s
response to treatment in anal cancer. Instead, physical examination, including digital rectal examination and palpation of the inguinal regions, is typically carried out during this period. Understanding the appropriate follow-up
protocols is essential for patient care.
15. A 55-year-old patient presents with symptoms suggestive of anal cancer. The
primary care physician is considering the initial approach to management.
Which of the following statements regarding the general approach to anal cancer is incorrect?
A. Radiation therapy combined with chemotherapy is the main treatment
modality for anal cancer.
B. Surgery is primarily considered for tumors that are not controlled with
chemoradiotherapy.
C. Early stages of anal cancer have a poor prognosis even with treatment.
D. Differentiating anal cancer from common hemorrhoids is essential for
diagnosis.
E. Diagnosis and treatment are centralized to specialized cancer clinics.
Answer: C
Explanation: Early stages of anal cancer have a poor prognosis even with
treatment. This statement is incorrect as the prognosis for early stages of
anal cancer is generally good with appropriate treatment.
16. A patient diagnosed with anal cancer is being discussed in a multidisciplinary
team meeting where treatment options are being considered. Which of the following statements about the treatment paradigm for anal cancer is incorrect?
A. Organ preservation by chemoradiotherapy has become the standard of care.
B. Radical surgical resection is the rst-line treatment for all stages of
anal cancer.
C. The incidence of anal cancer is increasing, particularly in HIV- positive males.
D. Understanding of pathophysiology and treatment has evolved signicantly
over the last 30years.
E. Risk factors for anal cancer have been identied and are key to management
strategies.
Answer: B
Explanation: Radical surgical resection is the rst-line treatment for all
stages of anal cancer. This statement is incorrect as the treatment paradigm
11 Anal Cancers
https://t.me/med1917
157
has shifted from radical surgical resection to organ preservation by
chemoradiotherapy.
17. A patient with squamous cell carcinoma of the anal canal is being evaluated for
treatment options. Which of the following statements about the management of
squamous cell carcinoma of the anal canal is incorrect?
A. Sphincter-saving chemoradiation has replaced abdominoperineal resection
as the rst-line therapy.
B. Surgeons play a crucial role in diagnosis, posttreatment surveillance, and
managing persistent or recurrent cancers.
C. Sentinel node biopsy is irrelevant in managing squamous cell carcinoma of
the anal canal.
D. In select cases, local excision has been employed as primary treatment in
conjunction with radiation and chemotherapy.
E. The introduction of HPV vaccines presents the potential for the disease’s
eradication.
Answer: C
Explanation: Sentinel node biopsy is irrelevant in managing squamous
cell carcinoma of the anal canal. This statement is incorrect as sentinel node
biopsy may identify patients who will benet from groin irradiation.
18. During a conference on anal cancer management, a debate arises about the
perioperative use of opioids. Which of the following statements regarding opioids’ role in cancer surgery is incorrect?
A. Opioids are the most commonly prescribed analgesics in the perioperative
period of cancer surgery.
B. The inuence of opioids on cancer recurrence or metastasis is well-
established and universally understood.
C. Recent ndings on opioids’ effects on cancer surgery outcomes have yielded
conicting results.
D. Prospective randomized trials are required to investigate opioids’ effects on
cancer surgery outcomes further.
E. Opioids continue to play an essential role in the perioperative period.
Answer: B
Explanation: The inuence of opioids on cancer recurrence or metastasis
is well-established and universally understood. This statement is incorrect
as the question of whether opioids could inuence recurrence or metastasis
remains unanswered.
19. A public health initiative is being developed to address the increasing incidence
of anal cancer in women. Which of the following statements regarding screening for anal cancer in women is incorrect?
A. The incidence of anal cancer is higher in women than in men in the general
population.
B. Most anal cancers are not associated with HPV infection.
C. Anal cancers are believed to be preceded by anal HSIL.
158
https://t.me/med1917
S. A. Aljiburi et al.
D. HPV-infected women and those with a history of lower genital tract neopla-
sia are at the highest risk.
E. Screening recommendations have been provided for women in high-
risk groups.
Answer: B
Explanation: Most anal cancers are not associated with HPV infection.
This statement is incorrect as most anal cancers are associated with HPV
infection.
20. You are evaluating a 50-year-old patient who has recently completed treatment
for anal cancer. During the follow-up visit, you discuss potential risk factors for
the recurrence of the disease. In the context of risk factors for the recurrence of
anal cancer, the incorrect statement is:
A. Primary tumor size >2 cm is a signicant risk factor for recurrence.
B. Nodal positivity increases the risk of recurrence.
C. Poor treatment adherence can contribute to recurrence.
D. Unnecessary chemotherapy dose reductions may increase the risk of
recurrence.
E. Treatment delay is a known risk factor for recurrence.
Answer: A
Explanation: Contrary to the statement, primary tumor size >5 cm, not
>2 cm, is associated with a higher risk of recurrence in anal cancer patients.
Understanding the specic risk factors for recurrence is vital for post-treatment management.
21. In the context of HIV in anal cancer, you are evaluating a 40-year-old patient
newly diagnosed with anal cancer who also has a history of HIV infection; the
incorrect statement is:
A. Newly diagnosed anal squamous cell cancer should be screened for HIV.
B. Newly diagnosed anal basal cell cancer should be screened for HIV.
C. Newly diagnosed anal adenocarcinoma should be screened for HIV.
D. Anal cancer is not a disease-dening condition for progression to acquired
immunodeciency syndrome (AIDS).
E. HIV-positive patients are treated similarly to non-HIV-positive individuals.
Answer: C
Explanation: While it is recommended to screen for HIV in patients with
anal squamous cell cancer, routine testing for HIV status in patients with
anal adenocarcinoma is not typically done unless the patient’s history suggests that screening may be warranted. It’s important to be aware of the
nuances in screening protocols for different histological types of anal cancer.
11 Anal Cancers
https://t.me/med1917
159
Bibliography
1. Hernandez BY, McDufe K, Zhu X, Wilkens LR, Killeen J, Kessel B, Wakabayashi MT,
Bertram CC, Easa D, Ning L, Boyd J, Sunoo C, Kamemoto L, Goodman MT.Anal human papillomavirus infection in women and its relationship with cervical infection. Cancer Epidemiol
Biomarkers Prev. 2005;14(11 Pt 1):2550–6. https://doi.org/10.1158/1055- 9965.EPI- 05- 0460.
PMID: 16284377; PMCID: PMC1475824
2. Kelly H, Chikandiwa A, Alemany Vilches L, Palefsky JM, de Sanjose S, Mayaud P.Association
of antiretroviral therapy with anal high-risk human papillomavirus, anal intraepithelial neoplasia, and anal cancer in people living with HIV: a systematic review and meta-analysis. Lancet
HIV. 2020;7(4):e262–78. https://doi.org/10.1016/S2352- 3018(19)30434- 5. Epub 2020 Feb 25
3. Serup-Hansen E, Linnemann D, Skovrider-Ruminski W, Høgdall E, Geertsen PF, Havsteen
H.Human papillomavirus genotyping and p16 expression as prognostic factors for patients
with American Joint Committee on Cancer stages I to III carcinoma of the anal canal. J Clin
Oncol. 2014;32(17):1812–7. https://doi.org/10.1200/JCO.2013.52.3464. Epub 2014 May 12
4. Barleben A, Mills S. Anorectal anatomy and physiology. Surg Clin North Am.
2010;90(1):1–15., Table of Contents. https://doi.org/10.1016/j.suc.2009.09.001.
5. Scholeeld JH, Harris D, Radcliffe A.Guidelines for management of anal intraepithelial neoplasia. Color Dis. 2011;13(Suppl 1):3–10.
6. Drake R, Wayne Vogl A, Mitchell AWM.Gray’s anatomy for students E-Book. 2019; ISBN:
9780323611053.
7. Pandey P. Anal anatomy and normal histology. Sex Health. 2012;9(6):513–6. https://doi.
org/10.1071/SH12034.
8. Ahmed A, Arbor TC, Qureshi WA.Anatomy, abdomen and pelvis: anal canal. 2023 May 22.
In: StatPearls [internet]. Treasure Island, FL: StatPearls Publishing; 2023.
9. Poynten IM, Jin F, Roberts JM, Templeton DJ, Law C, Cornall AM, Molano M, Machalek DA,
Carr A, Farnsworth A, Tabrizi S, Phillips S, Fairley CK, Garland SM, Hillman RJ, Grulich
AE.The natural history of anal high-grade squamous intraepithelial lesions in gay and bisexual men. Clin Infect Dis. 2021;72(5):853–61. https://doi.org/10.1093/cid/ciaa166. Erratum in:
Clin Infect Dis. 2022 May 30;74(10):1892
10. Welton ML, Steele SR, Goodman KA, etal. Anus. In: Amin MB, editor. AJCC cancer staging
manual. 8th ed. Chicago: AJCC; 2017. p.275.
11. Dapper H, Oechsner M, Hirche C, Münch S, Sauter C, Borm K, Peeken JC, Combs
SE, Habermehl D. Dosimetric comparison of different radiation techniques (IMRT vs.
3- dimensional) of the "true" (deep) ano-inguinal lymphatic drainage of anal cancer patients.
Radiat Oncol. 2018;13(1):227. https://doi.org/10.1186/s13014- 018- 1174- z. PMID: 30466454;
PMCID: PMC6249729
12. Lam AK, Goldblum JR.Tumours of the anal canal: introduction. In: WHO Classication of
Tumours Editorial Board, editor. WHO classication of tumours: digestive system tumours.
5th ed. Lyon: International Agency for Research on Cancer; 2019.
13. Das P, Bhatia S, Eng C, Ajani JA, Skibber JM, Rodriguez-Bigas MA, Chang GJ, Bhosale P,
Delclos ME, Krishnan S, Janjan NA, Crane CH.Predictors and patterns of recurrence after
denitive chemoradiation for anal cancer. Int J Radiat Oncol Biol Phys. 2007;68(3):794–800.
https://doi.org/10.1016/j.ijrobp.2006.12.052. Epub 2007 Mar 26
14. Frazer ML, Yang G, Felder S, McDonald J, Sanchez J, Dessureault S, Imanirad I, Carballido
E, Kim RD, Hoffe SE, Frakes JM.Determining optimal follow-up for patients with anal cancer following chemoradiation. Am J Clin Oncol. 2020;43(5):319–24. https://doi.org/10.1097/
COC.0000000000000673.
15. Hong TS, Pretz JL, Suh WW, Herman JM, Abdel-Wahab M, Azad N, Blackstock W, Das
P, Goodman KA, Jabbour SK, Jones WE III, Konski AA, Koong AC, Rodriguez-Bigas M,
Small W Jr, Thomas CR Jr, Zook J.Anal cancer. In: Anal cancer [internet]. Springer; 2013.
[cited 2023].
16. Salati SA, Kadi A.Anal cancer—a review. Int J Health Sci (Qassim). 2012;6(2):206–30.
160
https://t.me/med1917
17. Szmulowicz U, Wu JS. Squamous cell carcinoma of the anal canal: a review of the aetiology, presentation, staging, prognosis and methods available for treatment. Sex Health.
2012;9(6):593–609.
18. Connolly C, Buggy D. Opioids and tumour metastasis: does the choice of the anestheticanalgesic technique inuence outcome after cancer surgery? Curr Opin Anaesthesiol.
2016;29(4):468–74.
19. Moscicki AB, Darragh TM, Berry-Lawhorn JM, Roberts JM, Khan MJ, Boardman LA, Chiao
E, Einstein MH, Goldstone SE, Jay N, Likes W, Stier EA, Welton ML, Wiley DJ, Palefsky
JM.Screening for anal cancer in women. J Low Genit Tract Dis. 2015;19(3 Suppl 1):S27–42.
20. Gunderson LL, Moughan J, Ajani JA, Pedersen JE, Winter KA, Benson AB 3rd, Thomas
CR Jr, Mayer RJ, Haddock MG, Rich TA, Willett CG.Anal carcinoma: impact of TN category of disease on survival, disease relapse, and colostomy failure in US Gastrointestinal
Intergroup RTOG 98-11 phase 3 trial. Int J Radiat Oncol Biol Phys. 2013;87(4):638–45.
https://doi.org/10.1016/j.ijrobp.2013.07.035. Epub 2013 Sep 10. PMID: 24035327; PMCID:
PMC3938865
21. National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in
oncology. Available at: https://www.nccn.org/professionals/physician_gls (Accessed 18
May 2022).
S. A. Aljiburi et al.
Part II
https://t.me/med1917
Surgical Endocrine Oncology
Соседние файлы в папке @xirurgi_2025